WASHINGTON, March 11 /PRNewswire/ -- Proteome Systems Ltd. (ASX: PXL) CEO Dr Jenny Harry has been invited to join a panel with world health leaders in Washington DC at the Partnering for Global Health Forum sponsored by the Bill & Melinda Gates Foundation and organised by Bio Ventures in Global Health, and BIO the Biotechnology Industry Organization. [March 10-12, 2008]. http://pgh.bio.org/opencms/PGH/2008/program/program.jsp
The Forum follows a report last month from the World Health Organization (WHO) revealing that drug resistant tuberculosis has hit the highest levels ever recorded. According to a survey of over 90,000 TB patients in 81 countries, the WHO found that levels of multi-drug resistant (MDR) TB were far higher then expected. The survey also found cases in 45 countries of extensively drug resistant TB, which is virtually untreatable.
At the DC Forum Dr Harry is participating in a panel which will address 'Needs and Opportunities in Diagnostics: Creating Sustainable Solutions for the Developing World', and will draw on Proteome Systems' experience in its current development program for a rapid and accurate TB diagnostic test.
Proteome System's test aims to directly detect active TB by the presence of TB in the human body allowing for effective and timely treatment. It is planned that the test will diagnose TB within minutes, whereas the current tests for active TB take days to weeks. This will be a significant benefit in the management of this highly infectious disease.
The WHO estimates that there is an annual need for over 193 million point-of-care diagnostic tests for TB.
Proteome Systems has a collaboration and licensing agreement to advance the development and commercialization of the active TB diagnostic tests.
According to the US National Institute of Health, 8 million people worldwide, mostly in poorer countries where HIV is prevalent, develop active TB each year and 3 million die.
The other panelists with Dr Harry include: Jan Gheuens, MD, PhD (moderator), Senior Program Officer, Global Health Technologies, Bill & Melinda Gates Foundation; Gary M. Cohen, President, BD Medical, BD; Jean-Francois de Lavison, President, European Diagnostic Manufacturers Association; Lawrence A. Siebert, President and CEO, Chembio Diagnostics Inc., and Karen Hedine, President and CEO, Micronics.
Dr Harry said rapid and accurate diagnosis is critical to arrest transmission and to treat TB patients effectively and responsibly. "The primary need is for simple confirmatory and screening tests to distinguish active TB from other conditions with similar symptoms. The PXL test aims to allow direct detection of active TB in sputum and/or blood in a cost effective point of care format for rapid diagnosis," Dr Harry said.
About Proteome Systems
Proteome Systems Limited [ASX: PXL] is an Australian based diagnostics company that has extensive expertise in discovering biomarkers of disease and in diagnostic test development. Its focus is on clinical, nutritional, agricultural and environmental applications where there are large global markets and an unmet need for diagnostics.
Proteome Systems offers commercial partners a clear marketing advantage through its expertise in the development of novel, point-of-need diagnostic tests based on its proprietary test platform, DiagnostIQ(TM). It has the capability to work across the entire spectrum of diagnostic test development -- from identification and isolation of biomarkers, through point-of-need test design, clinical development or field testing to final product.
A collaboration and licensing deal has been entered into with Becton Dickinson to exploit PXL's biomarkers for the development of new TB diagnostic products. The Company also has a long standing working relationship with Bayer CropScience for the manufacture and sale of a WheatRite(R) test for crop quality, and for the development of other agricultural crop tests.
Additional information about Proteome Systems can be found at http://www.proteomesystems.com
Susan Fitzpatrick Ph: +1 650 798 5238 or +61 2 9006 1614
|SOURCE Proteome Systems Ltd.|
Copyright©2008 PR Newswire.
All rights reserved